Therapeutic approaches and outcomes in patients with larynx or hypopharynx high-grade neuroendocrine carcinoma: A single-center retrospective analysis.
larynx
neuroendocrine carcinoma
palliative therapy
small cell carcinoma
smoking
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
06
07
2021
received:
25
03
2021
accepted:
01
09
2021
pubmed:
16
9
2021
medline:
23
11
2021
entrez:
15
9
2021
Statut:
ppublish
Résumé
High-grade neuroendocrine carcinoma of the larynx (HG-NECL) is rare and aggressive with limited data regarding response to systemic therapy. We evaluated clinicopathological features, therapeutic approaches, and outcomes in patients with laryngeal or hypopharyngeal HG-NECL. Data were retrospectively collected through 1997-2020. Median disease-free (mDFS), progression-free (mPFS), and overall survival (mOS) were estimated using the Kaplan-Meier method. Fifteen patients were identified; most had locoregional (N = 7) or metastatic disease (N = 5). The main curative-intent treatment was chemoradiation concurrent with platinum-based chemotherapy; the rate of complete response was 78%. Most patients (80%) developed recurrence; the mDFS was 13.1 months. For the first-line palliative therapy, the ORR and mPFS were 50% and 3.1 months, respectively. For all patients, the mOS was 17.8 months, and 8.6 months for metastatic disease. Laryngeal HG-NEC is associated with high relapse rates and dismal prognosis for those with recurrent/metastatic disease. Novel therapeutic strategies are needed.
Sections du résumé
BACKGROUND
High-grade neuroendocrine carcinoma of the larynx (HG-NECL) is rare and aggressive with limited data regarding response to systemic therapy. We evaluated clinicopathological features, therapeutic approaches, and outcomes in patients with laryngeal or hypopharyngeal HG-NECL.
METHODS
Data were retrospectively collected through 1997-2020. Median disease-free (mDFS), progression-free (mPFS), and overall survival (mOS) were estimated using the Kaplan-Meier method.
RESULTS
Fifteen patients were identified; most had locoregional (N = 7) or metastatic disease (N = 5). The main curative-intent treatment was chemoradiation concurrent with platinum-based chemotherapy; the rate of complete response was 78%. Most patients (80%) developed recurrence; the mDFS was 13.1 months. For the first-line palliative therapy, the ORR and mPFS were 50% and 3.1 months, respectively. For all patients, the mOS was 17.8 months, and 8.6 months for metastatic disease.
CONCLUSION
Laryngeal HG-NEC is associated with high relapse rates and dismal prognosis for those with recurrent/metastatic disease. Novel therapeutic strategies are needed.
Identifiants
pubmed: 34524729
doi: 10.1002/hed.26865
pmc: PMC8595607
mid: NIHMS1738009
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3788-3795Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Head Neck. 2015 May;37(5):707-15
pubmed: 24596175
J Laryngol Otol. 2016 May;130(S2):S75-S82
pubmed: 27841116
Head Neck. 2000 Oct;22(7):680-6
pubmed: 11002323
Head Neck. 2017 Sep;39(9):1733-1743
pubmed: 28650113
J Oncol Pract. 2018 Jun;14(6):359-366
pubmed: 29894664
J Immunother Cancer. 2019 Mar 28;7(1):87
pubmed: 30922388
Ann Otol Rhinol Laryngol. 2016 Jun;125(6):464-9
pubmed: 26611246
Am J Clin Pathol. 2019 Nov 4;152(6):686-700
pubmed: 31415081
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
ORL J Otorhinolaryngol Relat Spec. 1991;53(4):210-9
pubmed: 1653928
J Clin Oncol. 2018 Apr 10;36(11):1143-1169
pubmed: 29172863
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Cancer Treat Rev. 1990 Mar;17(1):1-13
pubmed: 2171763
Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):594-601
pubmed: 26068492
Am J Surg Pathol. 2012 Feb;36(2):185-92
pubmed: 22082601
Cell. 2012 Sep 14;150(6):1121-34
pubmed: 22980976
Eur Respir J. 2001 Dec;18(6):1059-68
pubmed: 11829087
Clin Otolaryngol. 2012 Feb;37(1):63-6
pubmed: 22433139
Head Neck. 2008 Apr;30(4):518-24
pubmed: 18302254
Oral Oncol. 2012 Mar;48(3):211-5
pubmed: 22024350
Adv Ther. 2020 Jan;37(1):140-154
pubmed: 31802393
Head Neck. 2016 Aug;38(8):1271-7
pubmed: 27043228